HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.